We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Use of Patient Experience Data in Regulatory Decisions Varies Widely, Report Finds
FDA Use of Patient Experience Data in Regulatory Decisions Varies Widely, Report Finds
The FDA is increasingly using patient experience data when approving new drugs or biologics, but the agency’s use of the data “varies widely,” an agency-commissioned report concluded.